# Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

> **NCT06348173** · — · COMPLETED · sponsor: **Université de Montréal** · enrollment: 109 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab

## Key facts

- **NCT ID:** NCT06348173
- **Lead sponsor:** Université de Montréal
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348173, "Response and Remission to Treatment With Anti-IL5/IL5R Antagonists". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06348173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*